Sponsored by
Coherence Neuro, a company with ties to Neuralink, has reported early human feasibility testing of its implantable brain-computer interface during brain tumor surgeries in Australia. In three patients undergoing tumor resection, the device was temporarily placed in the brain for approximately 30 minutes to assess short-term safety and its ability to record electrical activity from tumor-related brain tissue before being removed. The procedures were designed as a proof-of-concept for intraoperative use rather than a therapeutic intervention.
The company has stated that it is developing the technology for longer-term implantation in patients with brain tumors, with an initial focus on glioblastoma (GBM), and plans to initiate a clinical trial in the coming year to evaluate safety and feasibility of extended implantation. While the technology could have future therapeutic potential, near-term clinical investigations are expected to focus on safety and feasibility, including electrical activity recording, with electrical stimulation therapy remaining a longer-term investigational goal.